Understanding the mechanisms that underlie the antitumour activity of non-steroidal anti-inflammatory drugs (NSAIDs) against colorectal cancer will allow the development of more effective and specific chemopreventative agents. Modulation of the NF-jB pathway has been implicated as a key effector of the antitumour effect of aspirin, but the effects of non-aspirin NSAIDs on this pathway have yet to be fully defined. Here, we demonstrate that sulindac, sulindac sulfone and indomethacin activate the NF-jB pathway in colorectal cancer cells, as determined by western blot analysis of cytoplasmic levels of IjBa and immunocytochemical analysis of nuclear NFjB/RelA. Furthermore, we show that all of these NSAIDs induce nucleolar translocation of the RelA subunit of NFjB. Using RelA deleted for the previously described nucleolar localization signal, we demonstrate that this response is causally involved in the apoptotic effects of these agents. Finally, we demonstrate that NSAIDmediated nucleolar translocation of RelA is associated with downregulation of NF-jB-driven transcription and of the NF-jB target gene, ICAM-1. These data identify nucleolar translocation of RelA and the associated repression of the NF-jB-driven transcription as a central molecular mechanism of NSAID-mediated growth inhibition and apoptosis. As well as providing new understanding of the molecular determinants of RelA function, these findings also have relevance to the development of novel chemotherapeutic and chemopreventative agents.
Understanding the mechanisms that underlie the antitumour activity of non-steroidal anti-inflammatory drugs (NSAIDs) against colorectal cancer will allow the development of more effective and specific chemopreventative agents. Modulation of the NF-jB pathway has been implicated as a key effector of the antitumour effect of aspirin, but the effects of non-aspirin NSAIDs on this pathway have yet to be fully defined. Here, we demonstrate that sulindac, sulindac sulfone and indomethacin activate the NF-jB pathway in colorectal cancer cells, as determined by western blot analysis of cytoplasmic levels of IjBa and immunocytochemical analysis of nuclear NFjB/RelA. Furthermore, we show that all of these NSAIDs induce nucleolar translocation of the RelA subunit of NFjB. Using RelA deleted for the previously described nucleolar localization signal, we demonstrate that this response is causally involved in the apoptotic effects of these agents. Finally, we demonstrate that NSAIDmediated nucleolar translocation of RelA is associated with downregulation of NF-jB-driven transcription and of the NF-jB target gene, ICAM-1. These data identify nucleolar translocation of RelA and the associated repression of the NF-jB-driven transcription as a central molecular mechanism of NSAID-mediated growth inhibition and apoptosis. As well as providing new understanding of the molecular determinants of RelA function, these findings also have relevance to the development of novel chemotherapeutic and chemopreventative agents. Keywords: chemoprevention; colon cancer; aspirin; cell adhesion; nucleolus; cell death There is substantial evidence indicating that nonsteroidal anti-inflammatory drugs (NSAIDs), including sulindac, sulindac metabolites and aspirin, have antitumour activity against colorectal cancer and can act as potential preventative agents (Grau et al., 2006) . However, these agents cannot be recommended for colorectal cancer prevention in healthy populations because of side-effect profiles (Bresalier et al., 2005; Wolfe et al., 1999) . Understanding the fundamental molecular mechanisms by which NSAIDs act against colorectal cancer is a central goal in the development of more specific and effective chemopreventative agents.
Studies from this laboratory have identified activation of the NF-kB signalling pathway as a key mechanism by which aspirin, the archetypal NSAID, exerts its antitumour activity (Stark et al., 2001; Din et al., 2004; Stark and Dunlop 2005) . NF-kB generally exists as a heterodimer of the p50 and RelA(p65) polypeptides, bound in an inactive state in the cytoplasm by the inhibitor protein IkB (Hoffmann et al., 2006) . Following cellular stimulation by a variety of agents, IkB is phosphorylated and then degraded by the proteasome, allowing NF-kB to translocate to the nucleus and regulate the expression of the target genes, including many that control cellular growth properties and apoptotic cell death (Dutta et al., 2006) . Previously, we established that pharmacologically relevant concentrations of aspirin induce degradation of IkBa and nuclear translocation of NF-kB in colorectal cancer cells in vitro and in colorectal neoplasia in vivo, and that this NF-kB response is essential for the proapoptotic effects of the agent (Stark et al., 2001 . We also established that upon activation of the NF-kB pathway by aspirin, the RelA component translocates from the cytoplasm to the nucleoplasm and then to the nuclear compartment, the nucleolus (Stark and Dunlop, 2005) . We identified a nucleolar localization signal (NoLS) at the N-terminus of RelA and, using a mutant deleted for this signal, demonstrated that nucleolar translocation of RelA is absolutely essential for aspirin-mediated apoptosis.
Non-aspirin NSAIDs also have potent antitumour activity against colorectal cancer and so, it is important for future drug design to determine whether these agents induce apoptosis of colorectal cancer cells by a similar mechanism to aspirin, or alternative pathways are utilized. Here, we report an investigation into the role of the NF-kB pathway in the proapoptotic effects of the non-aspirin NSAIDs sulindac, sulindac sulfone and indomethacin.
Firstly, we used western blot analysis to investigate the effects of these NSAIDs on cytoplasmic levels of the NF-kB inhibitor protein, IkBa, in colorectal cancer cells. Concentrations of the NSAIDs used in these studies are comparable with the levels achievable in humans (Brandli et al., 1991) and are previously shown to exert molecular effects in colorectal cancer cells (Smith et al., 2000) . In dose-response experiments, we found that 16 h of exposure to these agents appeared to have no effect on cytoplasmic levels of the protein (Figure 1a) . However, time-course studies using sulindac and sulindac sulfone indicated that these agents mediate a reduction in cytoplasmic levels of IkBa (indicative of proteasome-mediated degradation) within 1-2 h of treatment. Cytoplasmic levels of IkBa returned to basal levels within 8 h of treatment, explaining the apparent lack of effect at 16 h, described above. This transient IkB response is in contrast to the prolonged absence of IkB observed in response to aspirin (Stark et al., 2001) . Using immunocytochemistry, we found that NSAIDinduced IkB degradation precedes nuclear translocation of NF-kB/RelA (Figure 2b ) confirming that non-aspirin NSAIDs do indeed activate the NF-kB pathway. Annexin V apoptosis assays and western blot analysis for procaspase-3 confirmed that NSAID-mediated activation of the NF-kB pathway is associated with caspase-3 cleavage and apoptosis of colorectal cancer cells (Figures 1c and d) .
Previously, we established that the activation of NFkB signalling by aspirin results in translocation of the RelA component of NF-kB to the nucleolus and that this nucleolar translocation is causally involved in the apoptotic response to the agent (Stark and Dunlop, 2005) . To determine whether sulindac, sulindac sulfone and indomethacin act through a similar mechanism to aspirin, we next used immunocytochemistry to examine the cellular localization of endogenous RelA in colorectal cancer cells in response to the agents. Figure 2a demonstrates that RelA is predominantly cytoplasmic in untreated cells. Following 16 h treatment with each of the NSAIDs, there is a dramatic dose-dependent re-localization of RelA to the nucleus and specifically to Figure 1 IkBa degradation in response to NSAIDs. SW480 cells were cultured as previously described (Stark et al., 2001 ) then treated in low serum (0.5% FCS) medium with Sulindac (Sigma, Gillingham, UK), Sulindac Sulfone (MP Biomedicals), Indomethacin (Sigma) or aspirin (Sigma) at the concentrations specified for 16 h (a, c and d) or 0-8 h. (b) (a, b and d). western blot analysis, using antibodies to IkBa and procaspase-3, was performed on cytoplasmic extracts from treated cells as previously described (Stark et al., 2001) . AntiCopper/Zinc Superoxide Dismutase (Cu/Zn SOD) and anti-actin antibodies were used as controls for protein loading. Each blot is representative of at least three independent experiments. A dose-dependent decrease in procaspase-3 (indicative of cleavage of the protein consequent upon the induction of apoptosis) and a time-dependent decrease in IkBa are shown. (c) AnnexinV-FITC apoptosis assays were performed as described previously (Stark and Dunlop, 2005) . All the NSAIDs induce apoptosis in a dose-dependent manner. Results presented are the mean of at least three independent experiments ± standard error (s.e.). the nucleoli as defined by the lack of DAPI staining and the presence of the nucleolar proteins, nucleolin and fibrillarin (Figure 2b ). These data confirm that non-aspirin NSAIDs induce nucleolar translocation of RelA, implicating this effect in the induction of apoptosis by the agents. Time-course experiments using sulindac and sulindac sulfone indicated that RelA translocates firstly from the cytoplasm to the nucleoplasm in response to these agents, and then to the nucleolus at 2-5 h post-treatment (Figure 2c ). This sequential re-localization reflects our observations using aspirin to stimulate the NF-kB pathway (Figure 4c ).
Having shown that the non-aspirin NSAIDs induce nucleolar translocation of RelA, next we wished to determine whether this response is required for the proapoptotic effects of these agents. To this end, we utilized a RelA construct we generated that is deleted for the N-terminal NoLS (RelA D27-30) (Stark and Dunlop, 2005) . We have previously shown that the expression of this mutant RelA blocks aspirin-mediated nucleolar targeting of RelA, repression of NF-kB-driven transcription and apoptosis. Firstly, we investigated whether expression of this mutant construct abrogated nucleolar translocation of RelA mediated by nonaspirin agents. SW480 cells were transiently transfected with GFP-tagged wild-type RelA (RelA WT) or RelA D27-30, then the subcellular distribution of expressed proteins was monitored by live cell imaging. Both wild-type and mutant RelA localized predominantly in the cytoplasm prior to treatment. Exposure to sulindac, sulindac sulfone and to indomethacin caused an increase in nuclear levels of both WT and NoLS deleted RelA, confirming activation of the NF-kB pathway. However, while RelA WT accumulated specifically in the nucleolus in response to all three agents, RelA D27-30 accumulated in the nucleoplasm and was excluded from the nucleolus (Figure 3a) . There was no effect of NSAIDs on localization of GFP alone (data not shown). These Figure 1 . Immunocytochemistry was then performed with the specified antibodies as previously described (Stark and Dunlop, 2005) . Cells were analysed using fluorescent microscopy and images ( Â 63) captured using in-house scripts written for IPLab Spectrum 3.6. A time-and dose-dependent translocation of RelA from the cytoplasm to the nucleoplasm/nucleolus is shown. (b) Cells were treated with sulindac or indomethacin for 16 h. Immunocytochemistry demonstrates that the NSAID-induced RelA nuclear bodies (green) localize with areas devoid of DNA (absence of DAPI staining) and with the nucleolar markers nucleolin (red) and fibrillarin (red). 
.). (D)
The expression levels of WT and RelA D27-30 were comparable before and after NSAID treatment, as assessed by anti-GFP western blot analysis (Stark and Dunlop, 2005) . Actin was used as a loading control. (E) Expression of RelA deleted for the NoLS abrogates NSAID-mediated apoptosis. Annexin V-Biotin apoptosis assays were performed using an Annexin V-Biotin apoptosis detection kit along with a streptavidin-TxRd conjugate (Calbiochem, Nottingham, UK), as per the manufacturers instructions and as described previously (Stark and Dunlop, 2005) . Microscopy was used to determine the number of GFP and GFP-RelA expressing cells (identified in the FITC channel) undergoing apoptosis. At least 200 cells from a minimum of 10 independent fields of view were analysed. Results presented are the mean of three independent experiments ( ± s.e.). data confirm the critical importance of the N-terminal NoLS of RelA in nucleolar translocation of the protein.
We have previously shown that RelA D27-30 acts in a dominant-negative fashion in response to aspirin, in that expression of the mutant protein blocks aspirinmediated nucleolar translocation of endogenous protein. To determine whether exogenously expressing the NoLS deletion mutant also blocks nucleolar translocation of endogenous RelA in response to nonaspirin NSAIDs, we performed RelA immunocytochemistry on SW480 cells transfected with GFP-tagged WT or mutant RelA. We found that as expected, RelA WT showed nuclear and nucleolar localization of both endogenous and transfected protein in response to sulindac (Figure 3b ). However, in cultures expressing RelA D27-30 there was no nucleolar translocation of either mutant or endogenous protein in transfected cells. In contrast, adjacent non-transfected cells showed nucleolar accumulation of endogenous protein in response to the agent. These results confirm that the NoLS deletion mutant acts in a dominant negative fashion.
Next, using the dominant-negative RelA D27-30 mutant, we set out to establish whether there is a causal relationship between nucleolar localization of RelA and cell death induced by non-aspirin NSAIDs. Firstly, we studied effects on cell viability. We found that sulindac, sulindac sulfone and indomethacin each caused marked reduction in the number of viable SW480 cells in cultures expressing GFP alone or GFP-RelAWT (Figure 3c ), while these effects were abrogated in cultures expressing RelA D27-30. Phase-contrast microscopy confirmed that all the three agents mediate cell loss in cultures expressing GFP-RelAWT, while having a minimal effect on the number or morphology of cells in cultures expressing RelA D27-30 (data not shown). Transfection efficiency was comparable for all vectors and western blot analysis confirmed that WT and mutant protein were expressed at a similar level before and after NSAID treatment (Figure 3d ).
To confirm that the observed differential effects on viability of SW480 cells expressing RelA D27-30 or RelA WT exposed to sulindac, sulindac sulfone or indomethacin were due to differential induction of apoptosis, we next investigated the role of nucleolar localization of RelA in NSAID-induced apoptosis. Figure 3e demonstrates that NSAID-induced apoptosis is significantly inhibited by expression of RelA D27-30, contrasting with the increased apoptosis observed in cells expressing wild-type protein. All non-transfected cells underwent apoptosis to a similar extent in response to the agents (data not shown). These data provide compelling evidence that nucleolar targeting of RelA is of pivotal importance for the apoptotic effects of sulindac, sulindac sulfone and indomethacin. Furthermore, combined with our previous observations for aspirin, these findings indicate that these effects are relevant to NSAIDs as a class.
Constitutive NF-kB activity is increasingly recognized as a feature of carcinogenesis in various cancer types, including colorectal cancer (Perkins, 2004; Dutta et al., 2006) . One mechanism by which NF-kB activity promotes tumourigenesis is through persistent activation of NF-kB-dependent cancer-associated genes, including cell adhesion molecules, growth factors and antiapoptotic proteins. Based on our data demonstrating that aspirin-mediated nucleolar sequestration of RelA causes a decrease in NF-kB-driven transcription, previously we suggested a model whereby nucleolar targeting of RelA induces apoptosis in colorectal cancer cells by downregulating NF-kB activity at these promoters (Stark and Dunlop, 2005) . We show here that non-aspirin NSAIDs also mediate apoptosis through nucleolar targeting of RelA. Therefore, next we wished to further test this model by examining the effects of these agents on NF-kB-driven transcription. Using the 3 enhancer-CON-A (3 Â kB ConA-luc) NFkB-dependent luciferase reporter plasmid, we found that for all NSAIDs tested, nucleolar translocation of RelA was associated with a substantial, concentrationdependent reduction in basal levels of NF-kB-driven transcription (Figure 4a) .
The NF-kB target gene intracellular adhesion molecule-1 (ICAM-1) is an inducible, cell surface glycoprotein that plays an important role in cell-cell and cellextracellular matrix adhesion (Ledebur and Parks, 1995) . Expression of ICAM-1 is upregulated in colorectal cancer and it has been suggested that this contributes to colorectal carcinogenesis by allowing tumour cells to bind in a robust matrix at the primary Figure 4 NSAID-induced nucleolar targeting of RelA is associated with repression of NF-kB-driven transcription and decreased ICAM-1 expression. (a) SW480 cells were transiently transfected with 6 mg 3 Â kB ConA-Luc (a kind gift from Professor RT Hay, Dundee,UK) and 3 mg pCMVb (control) reporter plasmids using lipofectin (Invitrogen Life Technologies, Paisley, UK), treated with NSAIDs at the specified concentrations, then assayed for luciferase and b-galactosidase acivity using the manufacturers instructions (Promega, Southampton, UK), as described elsewhere (Stark and Dunlop, 2005) . Results presented are the percentage decrease in relative luciferase activity (calculated by dividing luciferase activity with b-gal activity), compared to the non-treated controls. The mean of three independent experiments ( ± s.e.) is shown. tumour site, as well as promoting metastatic invasion (Dippold et al., 1993; Vainer et al., 2006) . To further confirm that NSAID-mediated activation of the NF-kB pathway and nucleolar translocation of RelA are associated with downregulation of NF-kB-dependent genes, next we examined the effects of aspirin and sulindac on transcription of the ICAM-1 gene (Ledebur and Parks, 1995) . Using luciferase reporter assays, we found that activation of the NF-kB pathway by both agents was associated with a concentration-dependent decrease in basal levels of transcription driven by the full-length ICAM-1 promoter (Figure 4b ). We considered the possibility that this reduction in ICAM-1 transcription was caused by the induction of repressive NF-kB/RelA complexes (Campbell et al., 2004) , rather than nucleolar translocation of RelA per se. However, time-course studies indicated that at 1-2 h post-treatment, when aspirin/sulindac induced RelA was predominantly nucleoplasmic and excluded from the nucleolus, there was no change in transcription from the ICAM-1 promoter (Figures 4c and d) . Decreased ICAM-1 transcription was only observed following RelA nucleolar translocation (Figures 2c and 4c, d) . The agents had no effect on luciferase activity driven by a CMV promoter, indicating that the repressive effect is relatively specific (data not shown). Western blot analysis confirmed that NSAID effects on the ICAM-1 promoter were paralleled by a concentration-dependent decrease in expression of the protein in colorectal cancer cells. These data support the suggestion that nucleolar translocation of RelA inhibits the growth of colorectal cancer cells through downregulation of NF-kB-dependent genes. They also identify ICAM-1 as an NF-kB target gene that is repressed in association with the activation of the NF-kB pathway and nucleolar translocation of RelA. This is of particular relevance to cancer chemoprevention given the critical role of cell adhesion in tumour formation and progression.
Previously, we reported that aspirin-mediated degradation of IkBa is followed by prolonged absence of the protein from the cytoplasm, which is in contrast to the transient absence we observed here in response to non-aspirin NSAIDs (Figure 1b) . Since IkBa is a recognized target gene of NF-kB, one possible explanation for this difference might have been differential downstream effects of activation of the NF-kB pathway on transcription of the IkBa gene. However, our finding that stimulation of the NF-kB pathway is associated with repression of NF-kB-driven transcription to a similar extent after treatment with aspirin and non-aspirin NSAIDs make this explanation unlikely. It is now of extreme interest, to define the pathways upstream of NF-kB that are activated by these different agents. We and others have identified p38-mediated degradation of cyclinD1/inhibition of CDK4 as particularly interesting in this regard (Gardner et al., 2004; Sun and Sinicrope, 2005; Thoms et al., 2007) .
Taken together, the data presented here establish that non-aspirin NSAIDs stimulate the NF-kB pathway and induce nucleolar translocation of RelA, leading to induction of apoptosis of colorectal cancer cells. This finding is extremely relevant to cancer chemoprevention because, it supports our studies with aspirin and highlights the pivotal importance of this pathway as a target for novel chemopreventative agents. Identification of proteins/pathways that are involved in regulating the nuclear distribution of RelA may allow the design of small molecules that specifically target RelA to the nucleolus and mimic the chemopreventative effects of NSAIDs.
